冠状动脉支架置入术后并发症发生的遗传预测因素

Genetic Predictors of the Development of Complications after Coronary Stenting.

作者信息

Taizhanova Dana, Kalimbetova Akerke, Bodaubay Roza, Toleuova Aliya, Toiynbekova Rakhima, Beysenbekova Zhazira, Visternichan Olga, Tauesheva Zauresh, Kadyrova Irina, Babenko Dmitriy, Akhmaltdinova Lyudmila, Kolesnichenko Svetlana, Kolesnikova Yevgeniya, Avdienko Olga V, Akilzhanova Ainur, Gerotziafas Grigorios T

机构信息

Department of Internal Medicine Scientific and Research Center, Karaganda Medical University, Karaganda 100000, Kazakhstan.

Shared Resource Laboratory, Scientific and Research Center, Karaganda Medical University, Karaganda 100000, Kazakhstan.

出版信息

J Pers Med. 2022 Dec 22;13(1):14. doi: 10.3390/jpm13010014.

DOI:10.3390/jpm13010014

PMID:36675675

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9863814/

Abstract

Due to the fact that there are scientific discussions about the significance of gene polymorphisms in the risk of developing cardiovascular complications after a percutaneous coronary intervention, it is of interest to evaluate the genetic predictors of the development of cardiovascular events. This study is a molecular genetic study. Association with the genes of biomarkers for inflammation and immune response increases the risk of cardiovascular events: rs1234313 (TNFSF4): (A/G, OR-4.57 (2.35-8.87), ≤ 0.0001), (A/G-A/A, OR-3.14 (1.75-5.63), ≤ 0.0001), and (A/G, OR = 4.01 (2.19-7.36), ≤ 0.0001); rs3184504 (SH2D3); ATXN2: (C/T, OR-2.53 (1.28-5.01), T/T, OR-2.99 (1.13-7.92), = 0.017)), (C/T-T/T, OR-2.61 (1.35-5.07), = 0.000), and (OR-1.89 (1.15-3.09), = 0.009)). According to the lipid metabolism biomarker genes, rs2943634: (A/C OR-2.57 (1.18-5.62), = 0.013); according to the endothelial biomarker genes, rs2713604: (DNAJB8-AS1; GATA2): (C/T, OR-4.27 (2.35-7.76), ≤ 0.0001), (C/T-C/C, OR-4.13 (2.31-7.40), ≤ 0.0001), (OR-4.05 (2.24-7.30), ≤ 0.0001), and (C/T, OR-3.46 (1.99-6.00), ≤ 0.0001). The regression analysis found that in the presence of the rs2943634 gene polymorphism, the risk of late cardiovascular events increases by 4.007 times with 95% CI (1.502:10.692), = 0.006. The genes of biomarkers for the risk of cardiovascular events are rs1234313(TNFSF4), rs3184504 (SH2D3; ATXN2), rs2943634, and rs2713604 (DNAJB8-AS1; GATA2). The only predictor of the development of new cardiovascular events was rs2943634, which belongs to the group of lipid metabolism biomarkers.

摘要

由于存在关于基因多态性在经皮冠状动脉介入治疗后发生心血管并发症风险中的意义的科学讨论，因此评估心血管事件发生的遗传预测指标具有重要意义。本研究是一项分子遗传学研究。与炎症和免疫反应生物标志物基因的关联会增加心血管事件的风险：rs1234313（TNFSF4）：（A/G，比值比-4.57（2.35 - 8.87），P≤0.0001），（A/G - A/A，比值比-3.14（1.75 - 5.63），P≤0.0001），以及（A/G，比值比 = 4.01（2.19 - 7.36），P≤0.0001）；rs3184504（SH2D3）；ATXN2：（C/T，比值比-2.53（1.28 - 5.01），T/T，比值比-2.99（1.13 - 7.92），P = 0.017），（C/T - T/T，比值比-2.61（1.35 - 5.07），P = 0.000），以及（比值比-1.89（1.15 - 3.09），P = 0.009）。根据脂质代谢生物标志物基因，rs2943634：（A/C比值比-2.57（1.18 - 5.62），P = 0.013）；根据内皮生物标志物基因，rs2713604：（DNAJB8 - AS1；GATA2）：（C/T，比值比-4.27（2.35 - 7.76），P≤0.0001），（C/T - C/C，比值比-4.13（2.31 - 7.40），P≤0.0001），（比值比-4.05（2.24 - 7.30），P≤0.0001），以及（C/T，比值比-3.46（1.99 - 6.00），P≤0.0001）。回归分析发现，存在rs2943634基因多态性时，晚期心血管事件的风险增加4.007倍，95%置信区间为（1.502:10.692），P = 0.006。心血管事件风险生物标志物基因包括rs1234313（TNFSF4）、rs